{
  "ticker": "ABBV",
  "entities": [
    {
      "text": "AbbVie Inc.",
      "label": "ORG",
      "start": 0,
      "end": 11,
      "sentence": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "context": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of pos",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "ABBV",
      "label": "ORG",
      "start": 19,
      "end": 23,
      "sentence": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "context": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeli",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 223,
      "end": 229,
      "sentence": "Positive Sentiment:\nAbbVie’s pipeline advanced with encouraging updates across multiple clinical trials, including Phase 3 lutikizumab for hidradenitis suppurativa and early-stage studies in oncology and neurology.",
      "context": "dwinds limited further gains.\nPositive Sentiment:\nAbbVie’s pipeline advanced with encouraging updates acro",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "3",
      "label": "CARDINAL",
      "start": 324,
      "end": 325,
      "sentence": "Positive Sentiment:\nAbbVie’s pipeline advanced with encouraging updates across multiple clinical trials, including Phase 3 lutikizumab for hidradenitis suppurativa and early-stage studies in oncology and neurology.",
      "context": "across multiple clinical trials, including Phase 3 lutikizumab for hidradenitis suppurativa and earl",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 438,
      "end": 444,
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "context": "es in oncology and neurology.\nPositive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 200",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "IGI",
      "label": "ORG",
      "start": 463,
      "end": 466,
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "context": "ogy.\nPositive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up t",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "up to $1.9 billion",
      "label": "MONEY",
      "start": 512,
      "end": 530,
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "context": "IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.\nAbbVie License",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 566,
      "end": 572,
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "context": "o $1.9 billion, expanding its oncology portfolio.\nAbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Up to $1.9B+\nPositive Sentiment",
      "label": "MONEY",
      "start": 617,
      "end": 648,
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "context": "bbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:\nTechnical analysts noted a bullish golden cross",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "ABBV",
      "label": "ORG",
      "start": 701,
      "end": 705,
      "sentence": "Technical analysts noted a bullish golden cross on ABBV’s chart, a classic signal of upward momentum.",
      "context": "echnical analysts noted a bullish golden cross on ABBV’s chart, a classic signal of upward momentum.\nHer",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 771,
      "end": 777,
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "context": "sic signal of upward momentum.\nHere's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentimen",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 830,
      "end": 836,
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "context": "ock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi a",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Skyrizi",
      "label": "ORG",
      "start": 877,
      "end": 884,
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "context": "t:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring hea",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Novo Nordisk’s",
      "label": "ORG",
      "start": 889,
      "end": 903,
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "context": "TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing invest",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Wegovy",
      "label": "ORG",
      "start": 904,
      "end": 910,
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "context": "shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 914,
      "end": 916,
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "context": "ttle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.\nAbbVie",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 960,
      "end": 966,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "in Q2, underscoring heavy marketing investments.\nAbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Skyrizi",
      "label": "PRODUCT",
      "start": 969,
      "end": 976,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "nderscoring heavy marketing investments.\nAbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending t",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Novo",
      "label": "ORG",
      "start": 978,
      "end": 982,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "ng heavy marketing investments.\nAbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Wegovy",
      "label": "PRODUCT",
      "start": 985,
      "end": 991,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "y marketing investments.\nAbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral S",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 1007,
      "end": 1009,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "s.\nAbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "ABBV",
      "label": "ORG",
      "start": 1051,
      "end": 1055,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "ut in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with str",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "three",
      "label": "CARDINAL",
      "start": 1073,
      "end": 1078,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "g totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, r",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "3",
      "label": "CARDINAL",
      "start": 1156,
      "end": 1157,
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "context": "ng upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Se",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "today",
      "label": "DATE",
      "start": 1224,
      "end": 1229,
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "context": "llent Upside Potential\nNeutral Sentiment:\nDespite today’s gains, ABBV has lagged industry peers over rece",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "ABBV",
      "label": "ORG",
      "start": 1239,
      "end": 1243,
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "context": "tential\nNeutral Sentiment:\nDespite today’s gains, ABBV has lagged industry peers over recent sessions.\nA",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "recent sessions",
      "label": "DATE",
      "start": 1275,
      "end": 1290,
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "context": "oday’s gains, ABBV has lagged industry peers over recent sessions.\nAbbVie Inc. stock underperforms Wednesday when c",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie Inc.",
      "label": "ORG",
      "start": 1292,
      "end": 1303,
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "context": "V has lagged industry peers over recent sessions.\nAbbVie Inc. stock underperforms Wednesday when compared to co",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Wednesday",
      "label": "DATE",
      "start": 1324,
      "end": 1333,
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "context": "recent sessions.\nAbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "daily",
      "label": "DATE",
      "start": 1371,
      "end": 1376,
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "context": "ms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:\nAnalyst William Blair c",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "William Blair",
      "label": "PERSON",
      "start": 1411,
      "end": 1424,
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "context": "s despite daily gains\nNegative Sentiment:\nAnalyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY",
      "is_company": false,
      "is_person": true,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2 earnings",
      "label": "DATE",
      "start": 1429,
      "end": 1440,
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "context": "ins\nNegative Sentiment:\nAnalyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view t",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "2.88",
      "label": "MONEY",
      "start": 1455,
      "end": 1459,
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "context": "alyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pr",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "FY 2025",
      "label": "DATE",
      "start": 1472,
      "end": 1479,
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "context": "ir cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.\nW",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "11.82",
      "label": "MONEY",
      "start": 1493,
      "end": 1498,
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "context": "timates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.\nWilliam Blair Has Pe",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "William Blair",
      "label": "PERSON",
      "start": 1528,
      "end": 1541,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "5 EPS view to $11.82, citing pressure on margins.\nWilliam Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNeg",
      "is_company": false,
      "is_person": true,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 1569,
      "end": 1575,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "margins.\nWilliam Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales d",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 1576,
      "end": 1578,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": ".\nWilliam Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decl",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Imbruvica",
      "label": "PRODUCT",
      "start": 1608,
      "end": 1617,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology reve",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 1645,
      "end": 1651,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "e Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headw",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 1674,
      "end": 1676,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's O",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 1716,
      "end": 1722,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "enue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegativ",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 1753,
      "end": 1755,
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "context": "ds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:\nA federal judge dism",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 1811,
      "end": 1817,
      "sentence": "A federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law, removing a potential legal lever to defend pricing.",
      "context": "ts?\nNegative Sentiment:\nA federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law,",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Missouri",
      "label": "GPE",
      "start": 1833,
      "end": 1841,
      "sentence": "A federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law, removing a potential legal lever to defend pricing.",
      "context": ":\nA federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law, removing a potential leg",
      "is_company": false,
      "is_person": false,
      "is_location": true,
      "is_financial": false
    },
    {
      "text": "AbbVie",
      "label": "ORG",
      "start": 1940,
      "end": 1946,
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "context": "gal lever to defend pricing.\nFederal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Missouri",
      "label": "GPE",
      "start": 1960,
      "end": 1968,
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "context": "pricing.\nFederal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain",
      "is_company": false,
      "is_person": false,
      "is_location": true,
      "is_financial": false
    },
    {
      "text": "11m ago",
      "label": "DATE",
      "start": 1985,
      "end": 1992,
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "context": "sses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AI Generated",
      "label": "ORG",
      "start": 1993,
      "end": 2005,
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "context": "Vie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    }
  ],
  "relationships": [
    {
      "type": "SVO",
      "subject": "downgrades",
      "verb": "limited",
      "object": "gains",
      "sentence": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "importance": 6
    },
    {
      "type": "SVO",
      "subject": "Sentiment",
      "verb": "secured",
      "object": "rights",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "AbbVie",
      "verb": "secured",
      "object": "rights",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "AbbVie",
      "verb": "Licenses",
      "object": "ISB",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "analysts",
      "verb": "noted",
      "object": "cross",
      "sentence": "Technical analysts noted a bullish golden cross on ABBV’s chart, a classic signal of upward momentum.",
      "importance": 2
    },
    {
      "type": "SVO",
      "subject": "spending",
      "verb": "shows",
      "object": "battle",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "importance": 9
    },
    {
      "type": "SVO",
      "subject": "Skyrizi",
      "verb": "duke",
      "object": "it",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "importance": 10
    },
    {
      "type": "SVO",
      "subject": "ABBV",
      "verb": "lagged",
      "object": "peers",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "Blair",
      "verb": "cut",
      "object": "estimates",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "importance": 10
    },
    {
      "type": "SVO",
      "subject": "Drugs",
      "verb": "Aid",
      "object": "Results",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "importance": 16
    },
    {
      "type": "SVO",
      "subject": "judge",
      "verb": "dismissed",
      "object": "lawsuit",
      "sentence": "A federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law, removing a potential legal lever to defend pricing.",
      "importance": 3
    },
    {
      "type": "SVO",
      "subject": "judge",
      "verb": "tosses",
      "object": "lawsuit",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "importance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Inc.",
      "entity2_type": "ORG",
      "sentence": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc.",
      "entity1_type": "ORG",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "Positive Sentiment:\nAbbVie’s pipeline advanced with encouraging updates across multiple clinical trials, including Phase 3 lutikizumab for hidradenitis suppurativa and early-stage studies in oncology and neurology.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "IGI",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "up",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "to",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "1.9",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "billion",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "IGI",
      "entity1_type": "ORG",
      "entity2": "up",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "IGI",
      "entity1_type": "ORG",
      "entity2": "to",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "IGI",
      "entity1_type": "ORG",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "IGI",
      "entity1_type": "ORG",
      "entity2": "1.9",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "IGI",
      "entity1_type": "ORG",
      "entity2": "billion",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "MONEY",
      "entity2": "to",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "MONEY",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "MONEY",
      "entity2": "1.9",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "MONEY",
      "entity2": "billion",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "1.9",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "billion",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "$",
      "entity1_type": "MONEY",
      "entity2": "1.9",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "$",
      "entity1_type": "MONEY",
      "entity2": "billion",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "1.9",
      "entity1_type": "MONEY",
      "entity2": "billion",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Up",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "to",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "1.9B+",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "\n",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Positive",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "Up",
      "entity1_type": "MONEY",
      "entity2": "to",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Up",
      "entity1_type": "MONEY",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Up",
      "entity1_type": "MONEY",
      "entity2": "1.9B+",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Up",
      "entity1_type": "MONEY",
      "entity2": "\n",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Up",
      "entity1_type": "MONEY",
      "entity2": "Positive",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Up",
      "entity1_type": "MONEY",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "$",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "1.9B+",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "\n",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "Positive",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "MONEY",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "$",
      "entity1_type": "MONEY",
      "entity2": "1.9B+",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "$",
      "entity1_type": "MONEY",
      "entity2": "\n",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "$",
      "entity1_type": "MONEY",
      "entity2": "Positive",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "$",
      "entity1_type": "MONEY",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "1.9B+",
      "entity1_type": "MONEY",
      "entity2": "\n",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1.9B+",
      "entity1_type": "MONEY",
      "entity2": "Positive",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "1.9B+",
      "entity1_type": "MONEY",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "\n",
      "entity1_type": "MONEY",
      "entity2": "Positive",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "\n",
      "entity1_type": "MONEY",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Positive",
      "entity1_type": "MONEY",
      "entity2": "Sentiment",
      "entity2_type": "MONEY",
      "sentence": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Skyrizi",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Novo",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Nordisk",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Skyrizi",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Novo",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Nordisk",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "ORG",
      "entity2": "Novo",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "ORG",
      "entity2": "Nordisk",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "Nordisk",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Nordisk",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Nordisk",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Nordisk",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "’s",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "ORG",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "’s",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Wegovy",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Skyrizi",
      "entity2_type": "PRODUCT",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Novo",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "PRODUCT",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "three",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "PRODUCT",
      "entity2": "Novo",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "PRODUCT",
      "entity2": "Wegovy",
      "entity2_type": "PRODUCT",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "PRODUCT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "PRODUCT",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "PRODUCT",
      "entity2": "three",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "Skyrizi",
      "entity1_type": "PRODUCT",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "Wegovy",
      "entity2_type": "PRODUCT",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "three",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Novo",
      "entity1_type": "ORG",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Wegovy",
      "entity1_type": "PRODUCT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Wegovy",
      "entity1_type": "PRODUCT",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "Wegovy",
      "entity1_type": "PRODUCT",
      "entity2": "three",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Wegovy",
      "entity1_type": "PRODUCT",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "three",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "ABBV",
      "entity1_type": "ORG",
      "entity2": "three",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "ABBV",
      "entity1_type": "ORG",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "three",
      "entity1_type": "CARDINAL",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "today",
      "entity1_type": "DATE",
      "entity2": "ABBV",
      "entity2_type": "ORG",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "today",
      "entity1_type": "DATE",
      "entity2": "recent",
      "entity2_type": "DATE",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "today",
      "entity1_type": "DATE",
      "entity2": "sessions",
      "entity2_type": "DATE",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "ABBV",
      "entity1_type": "ORG",
      "entity2": "recent",
      "entity2_type": "DATE",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "ABBV",
      "entity1_type": "ORG",
      "entity2": "sessions",
      "entity2_type": "DATE",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "recent",
      "entity1_type": "DATE",
      "entity2": "sessions",
      "entity2_type": "DATE",
      "sentence": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Inc.",
      "entity2_type": "ORG",
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Wednesday",
      "entity2_type": "DATE",
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "daily",
      "entity2_type": "DATE",
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc.",
      "entity1_type": "ORG",
      "entity2": "Wednesday",
      "entity2_type": "DATE",
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc.",
      "entity1_type": "ORG",
      "entity2": "daily",
      "entity2_type": "DATE",
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Wednesday",
      "entity1_type": "DATE",
      "entity2": "daily",
      "entity2_type": "DATE",
      "sentence": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Blair",
      "entity2_type": "PERSON",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "earnings",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "2.88",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "earnings",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "2.88",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "earnings",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "2.88",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "earnings",
      "entity1_type": "DATE",
      "entity2": "2.88",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "earnings",
      "entity1_type": "DATE",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "earnings",
      "entity1_type": "DATE",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "earnings",
      "entity1_type": "DATE",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "2.88",
      "entity1_type": "MONEY",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "2.88",
      "entity1_type": "MONEY",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "2.88",
      "entity1_type": "MONEY",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "FY",
      "entity1_type": "DATE",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "FY",
      "entity1_type": "DATE",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "2025",
      "entity1_type": "DATE",
      "entity2": "11.82",
      "entity2_type": "MONEY",
      "sentence": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Blair",
      "entity2_type": "PERSON",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Imbruvica",
      "entity2_type": "PRODUCT",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "Imbruvica",
      "entity2_type": "PRODUCT",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "PERSON",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Imbruvica",
      "entity2_type": "PRODUCT",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Imbruvica",
      "entity2_type": "PRODUCT",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "Imbruvica",
      "entity1_type": "PRODUCT",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Imbruvica",
      "entity1_type": "PRODUCT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Imbruvica",
      "entity1_type": "PRODUCT",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Imbruvica",
      "entity1_type": "PRODUCT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "AbbVie",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Missouri",
      "entity2_type": "GPE",
      "sentence": "A federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law, removing a potential legal lever to defend pricing.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Missouri",
      "entity2_type": "GPE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "11",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "m",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "AbbVie",
      "entity1_type": "ORG",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Missouri",
      "entity1_type": "GPE",
      "entity2": "11",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Missouri",
      "entity1_type": "GPE",
      "entity2": "m",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Missouri",
      "entity1_type": "GPE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Missouri",
      "entity1_type": "GPE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Missouri",
      "entity1_type": "GPE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "m",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "m",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "m",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "m",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "AI",
      "entity1_type": "ORG",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "distance": 1
    }
  ],
  "key_phrases": [
    {
      "text": "AbbVie Inc.",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "a mix",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "positive pipeline updates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "strategic deals",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a bullish technical signal",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "analyst downgrades",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "legal headwinds",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "further gains",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie’s pipeline",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "encouraging updates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "multiple clinical trials",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Phase 3 lutikizumab",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "hidradenitis suppurativa",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "early-stage studies",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "IGI’s myeloma candidate",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a deal",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its oncology portfolio",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "IGI Myeloma Candidate ISB",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Technical analysts",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a bullish golden cross",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "ABBV’s chart",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a classic signal",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "upward momentum",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie Stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie’s TV ad spending",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a battle",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Novo Nordisk’s Wegovy",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "heavy marketing investments",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "AbbVie’s Skyrizi",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Novo’s Wegovy",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Q2 TV ad spending totals",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "three healthcare stocks",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "strong upside potential",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "analyst interest",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "3 Stocks",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Excellent Upside Potential",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "today’s gains",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "industry peers",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "recent sessions",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie Inc. stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "daily gains",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Analyst William Blair",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Q2 earnings estimates",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "FY 2025 EPS view",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "William Blair",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Pessimistic Outlook",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie Q2 Earnings",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Imbruvica sales decline",
      "type": "noun_chunk",
      "category": "trend"
    },
    {
      "text": "AbbVie’s oncology revenue",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "growth headwinds",
      "type": "noun_chunk",
      "category": "trend"
    },
    {
      "text": "AbbVie's Oncology Drugs",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Upcoming Q2 Results",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "A federal judge",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie’s lawsuit",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Missouri’s 340B drug pricing law",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a potential legal lever",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Federal judge",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "AbbVie lawsuit",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Missouri 340B law",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "$1",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$1",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$2.88",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$11.82",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "decline",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "revenue",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    }
  ],
  "important_sentences": [
    {
      "text": "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "importance_score": 51,
      "entity_count": 9,
      "financial_keyword_count": 7,
      "money_count": 0,
      "company_count": 3,
      "sentiment": "negative"
    },
    {
      "text": "Here's How to Play AbbVie Stock as it Reaches Golden Cross\nNeutral Sentiment:\nAbbVie’s TV ad spending shows a battle between Skyrizi and Novo Nordisk’s Wegovy in Q2, underscoring heavy marketing investments.",
      "importance_score": 39,
      "entity_count": 8,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 5,
      "sentiment": "neutral"
    },
    {
      "text": "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "importance_score": 34,
      "entity_count": 8,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 3,
      "sentiment": "positive"
    },
    {
      "text": "Analyst William Blair cut Q2 earnings estimates to $2.88 and trimmed FY 2025 EPS view to $11.82, citing pressure on margins.",
      "importance_score": 32,
      "entity_count": 8,
      "financial_keyword_count": 2,
      "money_count": 2,
      "company_count": 0,
      "sentiment": "neutral"
    },
    {
      "text": "Positive Sentiment:\nAbbVie secured rights to IGI’s myeloma candidate ISB 2001 in a deal worth up to $1.9 billion, expanding its oncology portfolio.",
      "importance_score": 30,
      "entity_count": 7,
      "financial_keyword_count": 1,
      "money_count": 1,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "Federal judge tosses AbbVie lawsuit over Missouri 340B law\nPosted 11m ago\nAI Generated. May Contain Errors.",
      "importance_score": 28,
      "entity_count": 7,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+\nPositive Sentiment:",
      "importance_score": 25,
      "entity_count": 8,
      "financial_keyword_count": 0,
      "money_count": 1,
      "company_count": 1,
      "sentiment": "positive"
    },
    {
      "text": "AbbVie Inc. (NYSE: ABBV) saw its stock rise amid a mix of positive pipeline updates, strategic deals, and a bullish technical signal, though analyst downgrades and legal headwinds limited further gains.",
      "importance_score": 23,
      "entity_count": 3,
      "financial_keyword_count": 3,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "Despite today’s gains, ABBV has lagged industry peers over recent sessions.",
      "importance_score": 15,
      "entity_count": 4,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "neutral"
    },
    {
      "text": "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:",
      "importance_score": 15,
      "entity_count": 4,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "negative"
    }
  ],
  "entity_statistics": {
    "total_entities": 49,
    "unique_entities": 26,
    "type_counts": {
      "ORG": 23,
      "CARDINAL": 3,
      "MONEY": 4,
      "DATE": 12,
      "PRODUCT": 3,
      "PERSON": 2,
      "GPE": 2
    },
    "type_distribution": {
      "ORG": 0.46938775510204084,
      "CARDINAL": 0.061224489795918366,
      "MONEY": 0.08163265306122448,
      "DATE": 0.24489795918367346,
      "PRODUCT": 0.061224489795918366,
      "PERSON": 0.04081632653061224,
      "GPE": 0.04081632653061224
    },
    "most_common_entities": [
      [
        "AbbVie",
        11
      ],
      [
        "Q2",
        5
      ],
      [
        "ABBV",
        4
      ],
      [
        "AbbVie Inc.",
        2
      ],
      [
        "3",
        2
      ],
      [
        "Skyrizi",
        2
      ],
      [
        "Wegovy",
        2
      ],
      [
        "William Blair",
        2
      ],
      [
        "Missouri",
        2
      ],
      [
        "IGI",
        1
      ]
    ],
    "entity_types_found": [
      "ORG",
      "CARDINAL",
      "MONEY",
      "DATE",
      "PRODUCT",
      "PERSON",
      "GPE"
    ],
    "company_entities": 23,
    "person_entities": 2,
    "financial_entities": 4,
    "entity_density": 0.17562724014336917
  },
  "financial_analysis": {
    "money_amounts": [
      "up to $1.9 billion",
      "Up to $1.9B+\nPositive Sentiment",
      "2.88",
      "11.82"
    ],
    "percentages": [],
    "companies": [
      "AbbVie Inc.",
      "ABBV",
      "AbbVie",
      "AbbVie",
      "IGI",
      "AbbVie",
      "ABBV",
      "AbbVie",
      "AbbVie",
      "Skyrizi",
      "Novo Nordisk’s",
      "Wegovy",
      "AbbVie",
      "Novo",
      "ABBV",
      "ABBV",
      "AbbVie Inc.",
      "AbbVie",
      "AbbVie",
      "AbbVie",
      "AbbVie",
      "AbbVie",
      "AI Generated"
    ],
    "people": [
      "William Blair",
      "William Blair"
    ],
    "dates": [
      "Q2",
      "Q2",
      "today",
      "recent sessions",
      "Wednesday",
      "daily",
      "Q2 earnings",
      "FY 2025",
      "Q2",
      "Q2",
      "Q2",
      "11m ago"
    ],
    "financial_terms": [
      "Stock",
      "revenue",
      "Earnings",
      "decline",
      "earnings",
      "stock",
      "growth"
    ],
    "financial_metrics": [],
    "market_indicators": []
  },
  "temporal_analysis": {
    "dates": [
      "Q2",
      "Q2",
      "today",
      "recent sessions",
      "Wednesday",
      "daily",
      "Q2 earnings",
      "FY 2025",
      "Q2",
      "Q2",
      "Q2",
      "11m ago"
    ],
    "time_expressions": [],
    "temporal_relationships": [
      "today",
      "Upcoming",
      "recent"
    ],
    "quarters": [
      "Q2",
      "Q2",
      "Q2 earnings",
      "Q2",
      "Q2",
      "Q2"
    ],
    "years": [
      "FY 2025"
    ],
    "time_periods": []
  },
  "sentiment_analysis": {
    "positive_words": 12,
    "negative_words": 4,
    "positive_ratio": 0.043010752688172046,
    "negative_ratio": 0.014336917562724014,
    "sentiment_score": 0.028673835125448032,
    "sentiment_label": "positive",
    "sentiment_strength": 0.028673835125448032,
    "confidence": 0.28673835125448033
  },
  "industry_analysis": {
    "dominant_industry": "healthcare",
    "industry_scores": {
      "tech": 1,
      "finance": 0,
      "healthcare": 8,
      "energy": 0,
      "retail": 0,
      "automotive": 0,
      "media": 2,
      "industrial": 0,
      "real_estate": 0,
      "telecom": 0,
      "food_beverage": 0,
      "travel": 0,
      "education": 0,
      "professional": 4,
      "mining": 0,
      "aerospace": 0,
      "environmental": 0,
      "cannabis": 0
    },
    "confidence": 0.5333333333333333
  },
  "market_analysis": {
    "market_sentiment": "bullish",
    "bullish_indicators": 2,
    "bearish_indicators": 1,
    "market_conditions": {
      "volatility": "normal",
      "volume": "normal",
      "trend": "bullish"
    },
    "trading_activity": "normal"
  },
  "competitor_analysis": {
    "companies_mentioned": [
      "AbbVie Inc.",
      "ABBV",
      "AbbVie",
      "AbbVie",
      "IGI",
      "AbbVie",
      "ABBV",
      "AbbVie",
      "AbbVie",
      "Skyrizi",
      "Novo Nordisk’s",
      "Wegovy",
      "AbbVie",
      "Novo",
      "ABBV",
      "ABBV",
      "AbbVie Inc.",
      "AbbVie",
      "AbbVie",
      "AbbVie",
      "AbbVie",
      "AbbVie",
      "AI Generated"
    ],
    "competitive_context": [
      "AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains\nNegative Sentiment:"
    ],
    "competitor_count": 23,
    "has_competitive_language": true
  },
  "risk_analysis": {
    "risk_sentences": [],
    "risk_count": 0,
    "risk_level": "low"
  },
  "opportunity_analysis": {
    "opportunity_sentences": [
      "AbbVie’s Skyrizi, Novo’s Wegovy duke it out in Q2 TV ad spending totals\nNeutral Sentiment:\nABBV was listed among three healthcare stocks with strong upside potential, reflecting analyst interest.\n3 Stocks With Excellent Upside Potential\nNeutral Sentiment:",
      "William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings\nNegative Sentiment:\nImbruvica sales decline may weigh on AbbVie’s oncology revenue in Q2, suggesting growth headwinds.\nHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?\nNegative Sentiment:",
      "A federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B drug pricing law, removing a potential legal lever to defend pricing."
    ],
    "opportunity_count": 3,
    "opportunity_level": "medium"
  },
  "processing_metadata": {
    "timestamp": "2025-07-17T03:50:48.316897",
    "model_used": "en_core_web_trf",
    "text_length": 2026
  }
}